KONU 61: HIV ENFEKSİYONUNUN TEDAVİSİ
KAYNAKLAR
1. Cohen, M.S., et al., Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011. 365(6): p. 493-505.
2. Cohen, M.S., et al., Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med, 2016. 375(9): p. 830-9.
3. Bavinton, B.R., et al., Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV, 2018. 5(8): p. e438-e447.
4. Rodger, A.J., et al., Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results
of a multicentre, prospective, observational study. Lancet, 2019. 393(10189): p. 2428-2438.
5. Connor, E.M., et al., Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study
Group. N Engl J Med, 1994. 331(18): p. 1173-80.
6. Townsend, C.L., et al., Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. Aids, 2014. 28(7): p. 1049-57.
7. Townsend, C.L., et al., Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. Aids, 2008. 22(8): p. 973-81.
8. Sibiude, J., et al., Update of Perinatal Human Immunodeficiency Virus Type 1 Transmission in France: Zero Transmission for 5482 Mothers on Continuous Antiretroviral Therapy From Conception
and With Undetectable Viral Load at Delivery. Clin Infect Dis, 2023. 76(3): p. e590-e598.
9. Hoffman, C., Overview-Classes of antiretrovirals and spesific drugs, in HIV 2023/2024, C. Hoffman and J.K. Rockstroh, Editors. 2023, Medizin Fokus Verlag: Germany. p. 43-47.
10. HIV/AIDS TANI İZLEM VE TEDAVİ EL KİTABI, D. Gökengin, et al., Editors., NOBEL TIP KİTABEVLERİ TİC. LTD. ŞTİ.
11. Kakuda, T.N., Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther, 2000. 22(6): p. 685-708.
12. Anderson, P.L., et al., Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. Aids, 2003. 17(15): p. 2159-68.
13. Athe M.N. Tsibris, M.S.H., Antiretroviral Therapy for Human Immunodeficiency Virus Infection, in Mandell, Douglas and Bennett’s principles and practice of infectious diseases, R.D. John E.
Bennett, Martin J. Blaser, Editor. 2020, Elsevier: Philadelphia,PA. p. 1739-1760.
14. Brinkman, K., et al., Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lan-
cet, 1999. 354(9184): p. 1112-5.
15. Boubaker, K., et al., Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis, 2001. 33(11): p. 1931-7.
16. Robbins, G.K., et al., Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 2003. 349(24): p. 2293-303.
17. Foster, R.H. and D. Faulds, Abacavir. Drugs, 1998. 55(5): p. 729-36; discussion 737-8.
18. EACS Guidelines version 12.0, October 2023.
19. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. Licence:
CC BY-NC-SA 3.0 IGO. 2021.
20. Walmsley, S.L., et al., Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med, 2013. 369(19): p. 1807-18.
21. Sax, P.E., et al., Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. New England Journal of Medicine, 2009. 361(23): p. 2230-2240.
22. Sax, P.E., et al., Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results. The Journal of Infectious Diseases, 2011.
204(8): p. 1191-1201.
23. Smith, K.Y., et al., Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. Aids, 2009.
23(12): p. 1547-56.
24. Stellbrink, H.J., et al., Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Clin Infect Dis, 2010. 51(8): p. 963-72.
25. Martin, A., et al., Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis, 2009. 49(10): p. 1591-601.
26. Martínez, E., et al., A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected
patients with virological suppression. J Acquir Immune Defic Syndr, 2009. 51(3): p. 290-7.
27. Moyle, G.J., et al., A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected indivi-
duals. PLoS One, 2015. 10(2): p. e0116297.
28. Mallal, S., et al., Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002. 359(9308): p. 727-
32.
29. Mallal, S., et al., HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med, 2008. 358(6): p. 568-79.
30. Hetherington, S., et al., Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet, 2002. 359(9312): p. 1121-2.
31. Kizmaz, M.A., et al., The Prevalence of HLA-B*57 Serotype Associated with Hypersensitivity Reactions in the Treatment of HIV İnfection in the Turkish Population. Current HIV Research,
2023. 21(4): p. 254-258.
32. Dorjee, K., et al., Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.
Int J Antimicrob Agents, 2018. 52(5): p. 541-553.
33. Campo, R., et al., SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected
patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis, 2013. 56(11): p. 1637-45.
34. Ding, X., et al., No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr, 2012. 61(4): p. 441-7.
35. O’Halloran, J.A., et al., Switching from abacavir to tenofovir disoproxil fumarate is associated with rises in soluble glycoprotein VI, suggesting changes in platelet-collagen interactions. Aids, 2018.
32(7): p. 861-866.
36. Taylor, K.A., et al., Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk. Br J Pharmacol, 2019.
176(7): p. 879-889.
37. Ziagen Kısa Ürün Bilgisi.
38. Izzedine, H., et al., Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron, 2001. 89(1): p. 62-7.
39. Ford, N., et al., Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable? Curr Opin HIV AIDS, 2017. 12(4): p. 334-338.
40. Gallant, J.E., et al., Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med, 2006. 354(3): p. 251-60.
41. Grant, R.M., et al., Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis, 2014. 14(9):
p. 820-9.
42. McCormack, S., et al., Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet,
2016. 387(10013): p. 53-60.
43. Frampton, J.E. and C.M. Perry, Emtricitabine: a review of its use in the management of HIV infection. Drugs, 2005. 65(10): p. 1427-48.
44. Kuritzkes, D.R., et al., Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated
patients. Aids, 1996. 10(9): p. 975-81.
45. Maguire, M., et al., Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI
2 and AVANTI 3 studies. Aids, 2000. 14(9): p. 1195-201.
46. Holdich, T., L.A. Shiveley, and J. Sawyer, Effect of Lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy vo-
lunteers. Antimicrob Agents Chemother, 2007. 51(8): p. 2943-7.
47. Cahn, P., et al., Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMI-
NI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, 2019. 393(10167): p. 143-155.
48. van Wyk, J., et al., Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance
of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis, 2020. 71(8): p. 1920-1929.
49. Miller, V., et al., The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med, 2002. 3(2): p. 135-45.
50. Stirrup, O.T., et al., Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. HIV Med, 2020. 21(5): p.
309-321.
51. Tisdale, M., et al., Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3’-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl
Acad Sci U S A, 1993. 90(12): p. 5653-6.
52. Podany, A.T., et al., Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Aids, 2018. 32(6): p. 761-765.
53. Sax, P.E., et al., Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised,
double-blind, phase 3, non-inferiority trials. Lancet, 2015. 385(9987): p. 2606-15.
54. Wang, H., et al., The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis. Medicine (Baltimore), 2016.
95(41): p. e5146.
55. Gallant, J.E., et al., Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1
infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV, 2016. 3(4): p. e158-65.
56. Mills, A., et al., Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-cont-
rolled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis, 2016. 16(1): p. 43-52.
57. Schafer, J.J., et al., Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. Open Forum Infect Dis,
2019. 6(10): p. ofz414.
58. Wohl, D., et al., Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and
Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr, 2016. 72(1): p. 58-64.
59. Venter, W.D.F., et al., Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med, 2019. 381(9): p. 803-815.
60. Sax, P.E., et al., Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis, 2020. 71(6): p. 1379-1389.
61. Eron, J.J., Jr., et al., Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, sing-
le-arm, multicentre, phase 3b trial. Lancet HIV, 2018.
62. Custodio, J.M., et al., Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment. Antimicrob Agents Chemother, 2016. 60(9): p. 5135-40.
63. Suo, Z. and K.A. Johnson, Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. J Biol Chem, 1998. 273(42): p. 27250-8.
64. Dadi, T.L., et al., Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis. AIDS Res Treat,
2017. 2017: p. 5792925.
65. Hall, A.M., et al., Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis, 2011. 57(5): p. 773-80.
66. Hill, A., et al., Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad, 2018. 4(2): p. 72-79.
67. Young, J., et al., Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Aids, 2012. 26(5): p. 567-75.
68. Bickel, M., et al., Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med, 2013. 14(10): p. 633-8.
69. Pozniak, A.L., et al., Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic,
and morphologic changes–a 96-week analysis. J Acquir Immune Defic Syndr, 2006. 43(5): p. 535-40.
70. Control, C.f.D. and Prevention, Achievements in public health. Reduction in perinatal transmission of HIV infection–United States, 1985-2005. MMWR. Morbidity and mortality weekly report,
2006. 55(21): p. 592-597.
71. D’Aquila, R.T., et al., Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial.
National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med, 1996. 124(12): p. 1019-30.
72. Piketty, C., et al., Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failures. Aids, 2004. 18(10):
p. 1469-71.
73. Grobler, J.A., et al., HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem, 2007. 282(11): p.
8005-10.
74. Zdanowicz, M.M., The pharmacology of HIV drug resistance. Am J Pharm Educ, 2006. 70(5): p. 100.
75. Sertoz, R., et al., Prevalence of Transmitted Drug Resistance among HIV-1 Patients in the Aegean Region: Results from the Western Part of Turkey. Current HIV Research, 2023. 21(2): p. 109-116.
76. HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey. AIDS Research and Human Retroviruses, 2016. 32(1): p. 26-31.
77. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. 2024.
Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. Accessed (March 2024). 2024.
78. Kikaire, B., et al., Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. Aids, 2007. 21(6): p. 733-7.
79. Hare, C.B., et al., Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis, 2008. 47(3): p.
421-4.
80. Chi, B.H., et al., Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal
HIV prevention: an open-label randomised trial. Lancet, 2007. 370(9600): p. 1698-705.
81. McIntyre, J.A., et al., Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med, 2009.
6(10): p. e1000172.
82. Hoffman, C., The optimal first-line therapy, in HIV 2023/2024, C. Hoffman and J.K. Rockstroh, Editors. 2023, Medizin Fokus Verlag: Germany. p. 157-183.
83. Molina, J.M., et al., Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-in-
feriority trial. Lancet HIV, 2018. 5(5): p. e211-e220.
84. Orkin, C., et al., Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Im-
munodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis, 2019. 68(4): p. 535-544.
85. Kumar, P., et al., Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr, 2021. 87(2): p.
801-805.
86. Wilby, K.J. and N.A. Eissa, Clinical Pharmacokinetics and Drug Interactions of Doravirine. Eur J Drug Metab Pharmacokinet, 2018. 43(6): p. 637-644.
87. Ankrom, W., et al., Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics. Antimicrob Agents Chemother, 2018. 62(8).
88. Smith, S.J., et al., Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. J Acquir Immune Defic Syndr, 2016. 72(5): p. 485-91.
89. Sterrantino, G., et al., Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents, 2019.
53(4): p. 515-519.
90. STOCRIN Kullanma Talimatı
91. Rockstroh, J.K., et al., Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from
STARTMRK. J Acquir Immune Defic Syndr, 2013. 63(1): p. 77-85.
92. Lennox, J.L., et al., Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised
controlled trial. Lancet, 2009. 374(9692): p. 796-806.
93. Mollan, K.R., et al., Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann
Intern Med, 2014. 161(1): p. 1-10.
94. Leutscher, P.D., et al., Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis, 2013. 45(8): p. 645-51.
95. Rihs, T.A., et al., Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med, 2006. 7(8): p. 544-8.
96. Marzolini, C., et al., Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids, 2001. 15(1): p. 71-5.
97. Tovar-y-Romo, L.B., et al., Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther, 2012. 343(3): p. 696-703.
98. Ford, N., et al., Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. Aids, 2014. 28 Suppl 2: p. S123-31.
99. Shubber, Z., et al., Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. Aids, 2013. 27(9): p. 1403-12.
100. Johnson, V.A., et al., Update of the Drug Resistance Mutations in HIV-1. Top HIV Med, 2008. 16(5): p. 138-45.
101. Katlama, C., et al., Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. Aids, 2009. 23(17): p. 2289-300.
102. Lazzarin, A., et al., Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled
trial. Lancet, 2007. 370(9581): p. 39-48.
103. Johnson, L.B. and L.D. Saravolatz, Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis, 2009. 48(8): p. 1123-8.
104. Madruga, J.V., et al., Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised
controlled phase III trial. Lancet, 2007. 370(9581): p. 49-58.
105. Katlama, C., et al., Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther, 2010. 15(7): p. 1045-52.
106. Durand, M., et al., Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec’s public health insurance
database. J Acquir Immune Defic Syndr, 2011. 57(3): p. 245-53.
107. Intelence (etravirin) Kısa Ürün Bilgisi. (cited 2024 21 Nisan); Available from: https://titck.gov.tr/storage/Archive/2021/kubKtAttachments/2_1beaa0a6-38ca-4bb3-9dcb-801431b23a30.pdf.
108. INTELENCE (etravirine) prescribing information. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INTELENCE-pi.pdf.
109. EDURANT (rilpivirin) Kısa Ürün Bilgisi. (cited 2024 21 Nisan); Available from: https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK-UYGUN-K%C3%9CB-%20
EDURANT.pdf_856e3c87-2a42-4373-ac90-5116efddb7d6.pdf.
110. Crauwels, H.M., et al., Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol, 2013. 53(8): p. 834-40.
111. Molina, J.M., et al., Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet, 2011. 378(9787): p. 238-46.
112. Cohen, C.J., et al., Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3,
randomised, non-inferiority trial. Lancet, 2011. 378(9787): p. 229-37.
113. Behrens, G., et al., Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled
ECHO/THRIVE subanalysis. AIDS Patient Care STDS, 2014. 28(4): p. 168-75.
114. Capetti, A.F., et al., Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. PLoS One, 2016. 11(10): p. e0164753.
115. Gantner, P., et al., Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med, 2017. 18(9): p. 704-708.
116. Llibre, J.M., et al., Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1
and SWORD-2 studies. Lancet, 2018. 391(10123): p. 839-849.
117. Carr, D.F., et al., Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis, 2013. 56(9): p. 1330-9.
118. Stern, J.O., et al., A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr, 2003. 34 Suppl 1: p. S21-33.
119. Kesselring, A.M., et al., Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Aids, 2009. 23(13): p. 1689-99.
120. Launay, O., et al., Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. Clin Infect
Dis, 2004. 38(8): p. e66-72.
121. Usach, I., V. Melis, and J.E. Peris, Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc, 2013. 16(1): p. 1-14.
122. Youle, M., Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother, 2007. 60(6): p. 1195-205.
123. Kempf, D.J., et al., Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother, 1997. 41(3): p.
654-60.
124. Lundgren, J., A. Mocroft, and L. Ryom, Contemporary protease inhibitors and cardiovascular risk. Curr Opin Infect Dis, 2018. 31(1): p. 8-13.
125. Bavinger, C., et al., Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One, 2013. 8(3): p. e59551.
126. Gardner, E.M., et al., Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. Aids, 2010. 24(3): p. 395-403.
127. Hirsch, M.S., et al., Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis, 2008. 47(2): p. 266-85.
128. Molina, J.M., et al., Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive
HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr, 2010. 53(3): p. 323-32.
129. Baril, J., et al., A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established
virological suppression after induction. HIV Med, 2014. 15(5): p. 301-10.
130. Cohen, C., et al., Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin, 2005. 21(10): p. 1683-
92.
131. Malan, N., et al., Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS Care, 2010. 22(6): p. 677-86.
132. Lennox, J.L., et al., Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized,
controlled equivalence trial. Ann Intern Med, 2014. 161(7): p. 461-71.
133. DeJesus, E., et al., Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir
disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet, 2012. 379(9835): p. 2429-2438.
134. Squires, K., et al., Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV, 2016. 3(9):
p. e410-e420.
135. Orrell, C., et al., Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated
women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Lancet HIV, 2017. 4(12): p. e536-e546.
136. Squires, K.E., et al., Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials, 2010. 11(2): p. 69-79.
137. Rotger, M., et al., Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis, 2005. 192(8): p. 1381-6.
138. Eholié, S.P., et al., Acute hepatic cytolysis in an HIV-infected patient taking atazanavir. Aids, 2004. 18(11): p. 1610-1.
139. Clotet, B., et al., Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two
randomised trials. Lancet, 2007. 369(9568): p. 1169-78.
140. Mills, A.M., et al., Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Aids, 2009. 23(13): p. 1679-88.
141. Tashima, K., et al., Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults. J Int AIDS Soc, 2014. 17(4
Suppl 3): p. 19772.
142. Clotet, B., et al., Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase
3b study. Lancet, 2014. 383(9936): p. 2222-31.
143. Costagliola, D., et al., Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within
the French Hospital Database on HIV. J Infect Dis, 2020. 221(4): p. 516-522.
144. De Meyer, S., et al., Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. Aids, 2009. 23(14): p. 1829-40.
145. Pozniak, A., et al., Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2. AIDS Res
Hum Retroviruses, 2008. 24(10): p. 1275-80.
146. Flexner, C., et al., Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week
randomized controlled trial. Clin Infect Dis, 2010. 50(7): p. 1041-52.
147. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. 2024.
148. Molina, J.M., et al., Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-in-
fected patients: 48 week efficacy and safety results of the CASTLE study. Lancet, 2008. 372(9639): p. 646-55.
149. Riddler, S.A., et al., Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med, 2008. 358(20): p. 2095-106.
150. Cahn, P., et al., Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-the-
rapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis, 2014. 14(7): p. 572-80.
151. Masquelier, B., et al., Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibi-
tor-experienced patients. Antimicrob Agents Chemother, 2002. 46(9): p. 2926-32.
152. Kempf, D.J., et al., Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates
from protease inhibitor-experienced patients. J Virol, 2001. 75(16): p. 7462-9.
153. Cameron, D.W., et al., Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet, 1998. 351(9102): p. 543-9.
154. Danner, S.A., et al., A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl
J Med, 1995. 333(23): p. 1528-33.
155. Evans-Jones, J.G., et al., Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis, 2010. 50(10): p. 1419-21.
156. Nair, V., HIV integrase as a target for antiviral chemotherapy. Rev Med Virol, 2002. 12(3): p. 179-93.
157. Engelman, A.N. and P.K. Singh, Cellular and molecular mechanisms of HIV-1 integration targeting. Cell Mol Life Sci, 2018. 75(14): p. 2491-2507.
158. Hazuda, D.J., et al., Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 2000. 287(5453): p. 646-50.
159. Hoffmann, C. and J.M. Llibre, Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors. AIDS Rev, 2019. 21(1): p. 4-10.
160. Hill, A., L. Waters, and A. Pozniak, Are new antiretroviral treatments increasing the risks of clinical obesity? J Virus Erad, 2019. 5(1): p. 41-43.
161. Tsiang, M., et al., Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother, 2016.
60(12): p. 7086-7097.
162. Saladini, F., et al., Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimic-
rob Agents Chemother, 2019. 64(1).
163. Cahn, P., et al., Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAI-
LING study. Lancet, 2013. 382(9893): p. 700-8.
164. Hightower, K.E., et al., Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integra-
se-DNA complexes. Antimicrob Agents Chemother, 2011. 55(10): p. 4552-9.
165. BIKTARVY Kısa Ürün Bilgisi. (cited 2024 21 Nisan); Available from: https://titck.gov.tr/storage/Archive/2019/kubKtAttachments/T%C4%B0TCK-UYGUN-K%C3%9CB-B%C4%B0K-
TARVY.pdf_17044366-4da9-485b-a78b-c759278818f4.pdf.
166. Wohl, D.A., et al., Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from
a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV, 2019. 6(6): p. e355-e363.
167. Stellbrink, H.J., et al., Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week
96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV, 2019. 6(6): p. e364-e372.
168. Daar, E.S., et al., Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-
1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV, 2018. 5(7): p. e347-e356.
169. Molina, J.M., et al., Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48
week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV, 2018. 5(7): p. e357-e365.
170. Kityo, C., et al., Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Mul-
ticenter, Active-Controlled, Phase 3, Noninferiority Trial. J Acquir Immune Defic Syndr, 2019. 82(3): p. 321-328.
171. Sax, P.E., et al., Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis, 2021. 73(2): p.
e485-e493.
172. Wang, R., et al., Rapid Initiation of Antiretroviral Therapy with Coformulated Bictegravir, Emtricitabine, Tenofovir Alafenamide Versus Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
in HIV-positive Men Who Have Sex with Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial. Clin Infect Dis, 2024.
173. Tenorio, C.H., et al., Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial. Int J Antimicrob
Agents, 2024: p. 107164.
174. Raffi, F., et al., Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind,
non-inferiority trial. Lancet Infect Dis, 2013. 13(11): p. 927-35.
175. Cahn, P., et al., Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Rando-
mized Clinical Trials. J Acquir Immune Defic Syndr, 2020. 83(3): p. 310-318.
176. Eron, J., et al., Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis. J Acquir
Immune Defic Syndr, 2020. 84(1): p. 60-65.
177. Cahn, P., et al., Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection. Aids, 2022. 36(1): p. 39-48.
178. Eron, J.J., et al., Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis, 2013. 207(5):
p. 740-8.
179. Castagna, A., et al., Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis, 2014.
210(3): p. 354-62.
180. Aboud, M., et al., Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1
and SWORD-2 studies. Lancet HIV, 2019. 6(9): p. e576-e587.
181. Zash, R., et al., Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med, 2019. 381(9): p. 827-840.
182. Min, S., et al., Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother, 2010. 54(1): p. 254-8.
183. Osterholzer, D.A. and M. Goldman, Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Clin Infect Dis, 2014. 59(2): p. 265-71.
184. Sax, P.E., et al., Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomi-
sed, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet, 2012. 379(9835): p. 2439-2448.
185. Arribas, J.R., et al., Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir
in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis, 2014. 14(7): p. 581-9.
186. Pozniak, A., et al., Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and
tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis, 2014. 14(7): p. 590-9.
187. Elion, R., et al., A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Im-
mune Defic Syndr, 2013. 63(4): p. 494-7.
188. Cooper, D.A., et al., Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med, 2008. 359(4): p. 355-65.
189. Steigbigel, R.T., et al., Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med, 2008. 359(4): p. 339-54.
190. Eron, J.J., et al., Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis, 2013.
13(7): p. 587-96.
191. Cahn, P., et al., Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised,
double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV, 2017. 4(11): p. e486-e494.
192. Landovitz, R.J., et al., Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med, 2021. 385(7): p. 595-608.
193. Letendre, S.L., et al., Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. J Antimic-
rob Chemother, 2020. 75(3): p. 648-655.
194. Spreen, W., et al., Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials, 2013. 14(5): p. 192-203.
195. Margolis, D.A., et al., Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection
(LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis, 2015. 15(10): p. 1145-1155.
196. Margolis, D.A., et al., Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet, 2017. 390(10101): p. 1499-1510.
197. Smith, G.H.R., et al., Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Open Forum Infect Dis, 2021. 8(9): p. ofab439.
198. Swindells, S., et al., Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med, 2020. 382(12): p. 1112-1123.
199. Orkin, C., et al., Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med, 2020. 382(12): p. 1124-1135.
200. Jaeger, H., et al., Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority
study. Lancet HIV, 2021. 8(11): p. e679-e689.
201. Dalgleish, A.G., et al., The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 1984. 312(5996): p. 763-7.
202. Doranz, B.J., et al., A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell, 1996. 85(7): p. 1149-58.
203. Shaik, M.M., et al., Structural basis of coreceptor recognition by HIV-1 envelope spike. Nature, 2019. 565(7739): p. 318-323.
204. HENNING GRUELL, P.S., FLORIAN KLEIN, Pathophysiology of HIV infection, in HIV 2023/2024, C. Hoffman and J.K. Rockstroh, Editors. 2023, Medizin Fokus Verlag Germany. p. 20-30.
205. Hoffman, C., ART 2024+: Beyond the horizon, in HIV 2023/2024, C. Hoffmann and J.K. Rockstroh, Editors. 2023, Medizin Fokus Verlag: Germany. p. 94-120.
206. Nettles, R.E., et al., Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis, 2012. 206(7): p. 1002-11.
207. Thompson, M., et al., Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized
controlled trial. Antivir Ther, 2017. 22(3): p. 215-223.
208. Charpentier, C., et al., Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 ‘non-B’-infected patients. J Antimicrob
Chemother, 2012. 67(6): p. 1459-61.
209. Lataillade, M., et al., Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet
HIV, 2020. 7(11): p. e740-e751.
210. Kozal, M., et al., Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. N Engl J Med, 2020. 382(13): p. 1232-1243.
211. Ackerman, P., et al., Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. Aids, 2021. 35(7): p. 1061-1072.
212. Connor, R.I., et al., Change in coreceptor use correlates with disease progression in HIV-1–infected individuals. J Exp Med, 1997. 185(4): p. 621-8.
213. Scarlatti, G., et al., In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med, 1997. 3(11): p. 1259-65.
214. Vandekerckhove, L.P., et al., European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis, 2011. 11(5): p. 394-407.
215. Whitcomb, J.M., et al., Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob
Agents Chemother, 2007. 51(2): p. 566-75.
216. Liverpool Drug Interaction Group, U.o.L., Interactions with Entry, Attachment and Capsid Inhibitors. 2023.
217. Gulick, R.M., et al., Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med, 2008. 359(14): p. 1429-41.
218. Fätkenheuer, G., et al., Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med, 2008. 359(14): p. 1442-55.
219. Hardy, W.D., et al., Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J
Acquir Immune Defic Syndr, 2010. 55(5): p. 558-64.
220. Cooper, D.A., et al., Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis,
2010. 201(6): p. 803-13.
221. Sierra-Madero, J., et al., Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials, 2010. 11(3): p. 125-32.
222. Gulick, R.M., et al., Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr, 2014. 65(1): p. 78-81.
223. Westby, M., et al., Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
J Virol, 2007. 81(5): p. 2359-71.
224. Emu, B., et al., Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med, 2018. 379(7): p. 645-654.
225. Norris D, M.J., Godofsky E, et al., TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when
compared with OBR alone in phase 2 study at 48 weeks (abstract no. THLB0218). in 16th International AIDS Conference. 2006.
226. Khanlou, H., et al. Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study. in 51st Interscience Conference on Antimicrobial Agents
and Chemotherapy. 2011.
227. Root, M.J., M.S. Kay, and P.S. Kim, Protein design of an HIV-1 entry inhibitor. Science, 2001. 291(5505): p. 884-8.
228. True, A.L., et al., Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. Pharmacotherapy, 2006. 26(12): p. 1679-86.
229. Lalezari, J.P., et al., Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 2003. 348(22): p. 2175-85.
230. Lazzarin, A., et al., Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med, 2003. 348(22): p. 2186-95.
231. Trottier, B., et al., Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic
Syndr, 2005. 40(4): p. 413-21.
232. Hicks, C.B., et al., Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48
weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label
trials. Lancet, 2006. 368(9534): p. 466-75.
233. Mink, M., et al., Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
J Virol, 2005. 79(19): p. 12447-54.
234. Lu, J., et al., Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr, 2006. 43(1): p. 60-4.
235. Walmsley, S., et al., Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis, 2003. 188(12): p. 1827-33.
236. McFadden, W.M., et al., Rotten to the core: antivirals targeting the HIV-1 capsid core. Retrovirology, 2021. 18(1): p. 41.
237. Selyutina, A., et al., GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors. iScience, 2022. 25(1): p. 103593.
238. Link, J.O., et al., Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature, 2020. 584(7822): p. 614-618.
239. Gupta, S.K., et al., Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled,
phase 2 trial. Lancet HIV, 2023. 10(1): p. e15-e23.
240. Segal-Maurer, S., et al., Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med, 2022. 386(19): p. 1793-1803.
241. Ogbuagu, O., et al., Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial. Lancet HIV, 2023. 10(8): p. e497-e505.
242. Tuan, J. and O. Ogbuagu, Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Expert Rev Anti Infect Ther, 2023. 21(6): p.
565-570.
243. Lundgren, J.D., et al., Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med, 2015. 373(9): p. 795-807.
244. Danel, C., et al., A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med, 2015. 373(9): p. 808-22.
245. Ambrosioni, J., et al., Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Medicine, 2023. 24(11): p. 1126-1136.
246. Thiébaut, R., et al., Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d’Epidémiologie du SIDA en Aquitaine (GECSA).
Aids, 2000. 14(8): p. 971-8.
247. Murray, J.M., et al., Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Aids, 2007. 21(17): p. 2315-21.
248. Cardozo, E.F., et al., Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. PLoS Pathog, 2017. 13(7): p.
e1006478.
249. Mocroft, A., et al., Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort
study. Lancet, 2007. 370(9585): p. 407-13.
250. Bouteloup, V., et al., Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. HIV Med, 2017. 18(1): p. 33-44.
251. Kelly, C., et al., Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes. PLoS One, 2016. 11(6): p. e0156099.
252. Gilson, R.J., et al., Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC)
Study. HIV Med, 2010. 11(2): p. 152-60.
253. Engsig, F.N., et al., Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis, 2014. 58(9): p. 1312-21.
254. Zoufaly, A., et al., Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis, 2011. 203(3): p. 364-71.
255. Sterne, J.A., et al., Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, 2009. 373(9672): p. 1352-63.
256. ANTIRETROVIRAL, T.S., Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization, 2015.
257. Ryom, L., et al., Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. HIV Med, 2016. 17(2): p. 83-8.
258. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
259. Koenig, S.P., et al., Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med, 2017. 14(7): p.
e1002357.
260. Ford, N., et al., Benefits and risks of rapid initiation of antiretroviral therapy. Aids, 2018. 32(1): p. 17-23.
261. Labhardt, N.D., et al., Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in
Lesotho: The CASCADE Randomized Clinical Trial. Jama, 2018. 319(11): p. 1103-1112.
262. Gandhi, R.T., et al., Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. Jama, 2023. 329(1):
p. 63-84.
263. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. Aids, 2008. 22(14): p. F17-24.
264. Sabin, C.A., et al., Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet,
2008. 371(9622): p. 1417-26.
265. Orkin, C., et al., Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV
Med, 2013. 14(1): p. 49-59.
266. Lennox, J.L., et al., Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic
Syndr, 2010. 55(1): p. 39-48.
267. Raffi, F., et al., Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143
randomised non-inferiority trial. Lancet, 2014. 384(9958): p. 1942-51.
268. Stellbrink, H.J., et al., Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. Aids, 2016. 30(8): p. 1229-38.
269. Li, J.Z., et al., No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial. Open Forum Infect Dis, 2019. 6(3): p. ofz056.
270. Gillman, J., et al., Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. J Antimicrob Chemother, 2019. 74(8): p. 2365-2369.
271. Ait-Khaled, M., et al., Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMI-
NI-1 and GEMINI-2 clinical studies. HIV Res Clin Pract, 2021. 23(1): p. 9-14.
272. Kaufmann, G.R., et al., CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med,
2003. 163(18): p. 2187-95.
273. Le Moing, V., et al., Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J
Infect Dis, 2002. 185(4): p. 471-80.
274. Hyle, E.P., P.E. Sax, and R.P. Walensky, Potential Savings by Reduced CD4 Monitoring in Stable Patients With HIV Receiving Antiretroviral Therapy. JAMA Internal Medicine, 2013. 173(18): p.
1746-1748.
275. Gale, H.B., et al., Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression? Clin Infect Dis, 2013. 56(9): p. 1340-3.
276. Pantaleo, G., et al., HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature, 1993. 362(6418): p. 355-8.
277. McManus, W., et al., No evidence for ongoing HIV replication in lymph nodes during suppressive ART, in 25th CROI 2018. 2017: Boston.
278. Hütter, G., et al., Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med, 2009. 360(7): p. 692-8.